Neuropsychiatric disorder specialist MapLight Therapeutics has made its debut on the Nasdaq, raising $251 million and arriving on the scene valued somewhere north of $800 million.

Illuminating its plans, neurological disease specialist MapLight said it would offer 14,750,000 shares of its common stock at $17.00 per share, which works out to an IPO of around $251m. The biotech ...

During BMS’ earnings call Thursday, CEO Chris Boerner, Ph.D., described Cobenfy as “delivering steady growth.” But the first-in-class drug still has a long way to go to fulfill its promise as a ...

Bristol Myers Squibb beat analyst and consensus estimates for the third quarter with $12.2 billion in sales, but executives ...

Cobenfy represents a breakthrough schizophrenia treatment with a novel mechanism, but limited long-term data requires ...

U.S. President Donald Trump's embrace of an old generic drug called leucovorin for use against a rare disorder that causes ...

The US Food and Drug Administration will take steps to streamline the process to develop generic versions of complex biological drugs, the agency announced Wednesday. The changes are meant to ...

The U.S. Food and Drug Administration is preparing to accelerate approvals for biosimilars, or generic versions of complex ...

Health Secretary Robert F. Kennedy Jr. and Medicare Administrator Dr. Mehmet Oz are scheduled to hold a news briefing ...

Fresenius Kabi has received the Food and Drug Administration’s permission for Conexxence (denosumab-bnht) and Bomyntra ...

Food and Drug Administration is preparing to accelerate approvals for biosimilars, or generic versions of complex biological ...

Effective Oct. 31 the FDA will require import certifications for all shrimp and spices within certain parts of Indonesia because of the risk of radioactivity. The move comes after levels of the ...